Literature DB >> 26154174

Transitioning to HIV Pre-Exposure Prophylaxis (PrEP) from Non-Occupational Post-Exposure Prophylaxis (nPEP) in a Comprehensive HIV Prevention Clinic: A Prospective Cohort Study.

Reed A C Siemieniuk1, Nirojini Sivachandran1, Pauline Murphy2, Andrea Sharp2, Christine Walach2, Tania Placido2, Isaac I Bogoch1,2,3.   

Abstract

The uptake of pre-exposure prophylaxis (PrEP) for HIV prevention remains low. We hypothesized that a high proportion of patients presenting for HIV non-occupational post-exposure prophylaxis (nPEP) would be candidates for PrEP based on current CDC guidelines. Outcomes from a comprehensive HIV Prevention Clinic are described. We evaluated all patients who attended the HIV Prevention Clinic for nPEP between January 1, 2013 and September 30, 2014. Each patient was evaluated for PrEP candidacy based on current CDC-guidelines and subjectively based on physician opinion. Patients were then evaluated for initiation of PrEP if they met guideline suggestions. Demographic, social, and behavioral factors were then analyzed with logistic regression for associations with PrEP candidacy and initiation. 99 individuals who attended the nPEP clinic were evaluated for PrEP. The average age was 32 years (range, 18-62), 83 (84%) were male, of whom 46 (55%) men who had have sex with men (MSM). 31 (31%) met CDC guidelines for PrEP initiation, which had very good agreement with physician recommendation (kappa=0.88, 0.78-0.98). Factors associated with PrEP candidacy included sexual exposure to HIV, prior nPEP use, and lack of drug insurance (p<0.05 for all comparisons). Combining nPEP and PrEP services in a dedicated clinic can lead to identification of PrEP candidates and may facilitate PrEP uptake. Strategies to ensure equitable access of PrEP should be explored such that those without drug coverage may also benefit from this effective HIV prevention modality.

Entities:  

Mesh:

Year:  2015        PMID: 26154174     DOI: 10.1089/apc.2015.0014

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  6 in total

1.  Concerns about a study on sexually transmitted infections after initiation of HIV preexposure prophylaxis.

Authors:  Julia L Marcus; Jonathan E Volk; Jonathan M Snowden
Journal:  AIDS       Date:  2018-04-24       Impact factor: 4.177

2.  Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Authors:  Kenneth H Mayer; Daniel Jones; Catherine Oldenburg; Sachin Jain; Marcy Gelman; Shayne Zaslow; Chris Grasso; Matthew J Mimiaga
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

3.  HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.

Authors:  Tanya L Kowalczyk Mullins; Gregory Zimet; Michelle Lally; Jiahong Xu; Sarah Thornton; Jessica A Kahn
Journal:  AIDS Patient Care STDS       Date:  2017-12       Impact factor: 5.078

4.  High prevalence of syndemic health problems in patients seeking post-exposure prophylaxis for sexual exposures to HIV.

Authors:  Steven A Morrison; Deborah Yoong; Trevor A Hart; Paul MacPherson; Isaac Bogoch; Vishalini Sivarajah; Kevin Gough; Mark Naccarato; Darrell H S Tan
Journal:  PLoS One       Date:  2018-05-23       Impact factor: 3.240

5.  Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis.

Authors:  Kimberly A Koester; Robert M Grant
Journal:  Clin Infect Dis       Date:  2015-09-01       Impact factor: 9.079

6.  Use of an HIV-risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk.

Authors:  James Wilton; Taylor Kain; Shawn Fowler; Trevor A Hart; Troy Grennan; John Maxwell; Darrell Hs Tan
Journal:  J Int AIDS Soc       Date:  2016-06-03       Impact factor: 5.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.